Clinical Trial Update: A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis [Phase 4]

View source ↗

Summary

A Phase 4 study evaluating the safety and efficacy signals of baricitinib in rheumatoid arthritis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Baricitinib (Olumiant) (baricitinib)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Rheumatoid Arthritis | Phase 4 | Status: COMPLETED